文献速递头颈部肿瘤放疗放疗物理与技术

头颈部鳞状细胞癌辅助再照射的质子治疗

Adjuvant Reirradiation With Proton Therapy in Head and Neck Squamous Cell Carcinoma.
PubMed 文献 · Adv Radiat Oncol · 2023-12-10

该回顾性分析纳入22例既往接受过放疗的头颈部鳞状细胞癌患者,在挽救性手术后接受质子辅助再照射。86%完成再照射且无治疗延迟,3例出现≥3级急性毒性,4例影像学诊断骨放射性坏死;2年局部区域无复发生存率为64.8%,总生存率为79.2%。作者认为该方案耐受性良好且局部控制合理,但似乎与骨放射性坏死风险相关。

要点

  • 22例头颈部鳞状细胞癌患者挽救性术后接受质子辅助再照射,86%完成治疗且无报告的治疗延迟。
  • 3例发生≥3级急性不良事件毒性,再照射期间无患者需要放置肠内喂养管。
  • 4例影像学诊断骨放射性坏死,其中2例需要手术干预。

核心结论

  • 作者认为,头颈部鳞状细胞癌的辅助再照射耐受性良好,在这一高危队列中提供了合理的局部控制,但似乎与骨放射性坏死风险相关。
  • 作者指出,进一步研究和更长随访可能有助于确定该患者人群的最佳管理。

研究设计与样本

  • 回顾性分析头颈部鳞状细胞癌患者,在本机构接受挽救性手术后接受质子辅助再照射,时间跨度1.5年。
  • 所有纳入患者既往均接受过放疗,队列共22例。
  • 采用Kaplan-Meier法评估局部区域无复发生存和总生存。

主要发现

  • 根据不良病理特征,辅助再照射剂量为66 Gy(占队列32%)或60 Gy(占68%),同步(59%)或不同步(41%)全身治疗。
  • 大多数(86%)完成再照射且无报告的治疗延迟;3例发生≥3级急性不良事件通用术语标准毒性,再照射期间无患者需要放置肠内喂养管。
  • 中位随访21.0个月(IQR,11.7-25.2个月);5例活检证实的疾病复发,再照射后中位5.9个月(IQR,3.8-9.7个月)。
  • 局部区域无复发生存率在6、12、24个月分别为95.2%、70.2%、64.8%;总生存率在6、12、24个月分别为100%、79.2%、79.2%。
  • 4例影像学诊断骨放射性坏死,再照射后中位13.2个月(IQR,8.7-17.4个月),其中2例需要手术干预。

局限性

  • 原文为回顾性分析。
  • 作者指出需要进一步研究和更长随访以确定该患者人群的最佳管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: For patients with head and neck squamous cell carcinoma (HNSCC), locoregional failure and second primary tumors are common indications for adjuvant reirradiation (re-RT). Given an absence of clear consensus on the role of adjuvant re-RT, we sought to assess histopathologic risk factors of patients with HNSCC and their resulting outcomes after adjuvant re-RT with proton therapy. METHODS AND MATERIALS: We conducted a retrospective analysis of patients with HNSCC who underwent salvage surgery at our institution followed by adjuvant re-RT with proton therapy over 1.5 years. All included patients received prior radiation therapy. The Kaplan-Meier method was used to evaluate locoregional recurrence-free survival and overall survival. RESULTS: The cohort included 22 patients, with disease subsites, including oropharynx, oral cavity, hypopharynx, larynx, and nasopharynx. Depending on adverse pathologic features, adjuvant re-RT to 66 Gy (32% of cohort) or 60 Gy (68%), with (59%) or without (41%) concurrent systemic therapy was administered. The majority (86%) completed re-RT with no reported treatment delay; 3 patients experienced grade ≥3 acute Common Terminology Criteria for Adverse Events toxicity and no patient required enteral feeding tube placement during re-RT. Median follow-up was 21.0 months (IQR, 11.7-25.2 months). Five patients had biopsy-proven disease recurrences a median of 5.9 months (IQR, 3.8-9.7 months) after re-RT. Locoregional recurrence-free survival was 95.2%, 70.2%, 64.8% at 6, 12, and 24 months, respectively. OS was 100%, 79.2%, and 79.2% at 6, 12, and 24 months, respectively. Four patients had osteoradionecrosis on imaging a median of 13.2 months (IQR, 8.7-17.4 months) after re-RT, with 2 requiring surgical intervention. CONCLUSIONS: Adjuvant re-RT for patients with HNSCC was well-tolerated and offered reasonable local control in this high-risk cohort but appears to be associated with a risk of osteoradionecrosis. Additional study and longer follow-up could help define optimal patient management in this patient population.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hsieh K, Hotca AE, Dickstein DR, et al. Adjuvant Reirradiation With Proton Therapy in Head and Neck Squamous Cell Carcinoma. Adv Radiat Oncol. 2023. PMID: 38778826. doi:10.1016/j.adro.2023.101418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。